tirzepatide ban update WADA just added (mounjaro) to the 2026 Monitoring Program compound tirzepatide ban update ๐ขImportant
Description
The first biosimilar formulation of a GLP-1 receptor agonist, liraglutide, has recently been marketed, at a lower acquisition cost than the original formulation, whilst oral semaglutide remains the only currently available GLP-1 receptor agonist that is administered orally
A busy science-filled day #ENDO2018 @TheEndoSociety Suggest calibrating your St
Researchers are investigating Retatrutide because of its multi-receptor activity and potential role in metabolic pathway studies
Learn why weight loss stalls and how to restart your metabolism safely with guidance from ER of Irving
